Amgen will present findings from clinical studies of both branded and investigational drugs.
Amgen will present data from multiple different studies at the American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting.
They will be presenting data from studies that explored the use of branded drugs, including Enbrel (etanercept), Prolia (denosumab) and Amjevita (adalimumab-atto). They will also be presenting findings from studies of investigational drugs, including ABP 710 (infliximab biosimilar candidate) and romosozumab.
In total, Amgen reported that they will be presenting 21 sets of results from different studies. A majority of the studies presented will be regarding Enbrel, the company’s top-earner.
Enbrel is a soluble form of a TNF receptor that first received FDA approval in 1998 for rheumatoid arthritis. It has since received approval for poylarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
Enbrel was recently approved to treat pediatric patients with psoriasis.
"The need for an effective treatment for chronic moderate-to-severe pediatric psoriasis patients is high, and safety is always a concern when it comes to treating children. Enbrel has over a decade of experience in adult moderate to severe plaque psoriasis, and that proven track record matters to healthcare professionals, as well as the parents of children with moderate-to-severe plaque psoriasis," Sean E. Harper, MD, executive vice president of Research and Development at Amgen said about the drug’s recent approval. "Today's FDA approval shows that innovation doesn't stop with a drug's first market approval, and further reflects Amgen's commitment to continually unlock and expand the therapeutic potential of our medicines in the hopes of filling unmet patient needs."
Enbrel’s efficacy is further confirmed by the multiple studies Amgen will be presenting at the conference, according to a press release.
Additionally, Amgen will also provide real-world insights about patients with rheumatologic and bone disorders. They will specifically discuss what the disease means for the patient, and how their needs can be better met.
Amgen will present information about the long-term clinical and economic impact of these diseases on both patients and the healthcare system, they said.
“As a leader in rheumatology and bone health, we remain committed to not only establishing the full therapeutic potential of our investigational products, but also to investing in continued research of our marketed products and establishing their value,” said Sean E. Harper, MD, executive vice president of Research and Development at Amgen. “We are pleased to be presenting a wide breadth of data across our diverse treatment portfolio to spark important dialogue about addressing patient needs in devastating diseases, such as rheumatoid arthritis, psoriatic arthritis and osteoporosis.”